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Abstract Fibrillin molecules form the structural framework of
elastic fibrillin-rich microfibrils of the extracellular matrix. We
have investigated the proteolysis of recombinant fibrillin
molecules by five matrix metalloproteinases. Cleavage sites were
defined at the carboxy-terminal end of the fibrillin-1 proline-rich
region and the corresponding fibrillin-2 glycine-rich region (exon
10), and within exon 49 towards the carboxy-terminus of
fibrillin-1. Cleavage at these sites is predicted to disrupt the
structure and function of the fibrillin-rich microfibrils.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Fibrillin-rich micro¢brils are extensible linear polymers of
the extracellular matrix [1]. They have a characteristic beaded
structure with a 10^14 nm diameter and an average axial
periodicity of V56 nm in untensioned state [2]. Their impor-
tance to connective tissue integrity was highlighted by linkage
of mutations in the genes for ¢brillin-1 and ¢brillin-2 to the
heritable connective tissue disorders Marfan syndrome and
congenital contractural arachnodactyly, respectively [3]. Fi-
brillin molecules are the principal structural components of
micro¢brils. They are large rod-like (V350 kDa) glycopro-
teins with a multidomain structure dominated by repeating
cbEGF-like domains interspersed with eight-cysteine-contain-
ing TB modules [4,5]. Towards the amino-terminus of ¢brillin-
1 is a unique proline-rich region which may act as a molecular
hinge; ¢brillin-2 has a corresponding glycine-rich region.
Although the molecular organisation of ¢brillin molecules in
micro¢brils remains ill de¢ned, immunolocalisation studies
indicate that amino- and carboxy-termini are located in the
proximity of the beads and the proline-rich region within the
interbead region [6].
Progressive loss of connective tissue elasticity in ageing and
in£ammatory conditions may involve cumulative proteolytic
damage to the micro¢brillar arrays that endow tissues with
long-range elasticity and form structural elements of elastic
¢bres [7,8]. In chrono- and photo-aged skin which has reduced
elasticity, we have recently shown that papillary dermal mi-
cro¢brillar networks are severely disrupted [9]. We have also
demonstrated that ¢brillin molecules and micro¢brils are
highly susceptible to degradation by serine proteinases [10].
The MMPs, a family of zinc-dependent enzymes secreted by
mesenchymal cells, macrophages and polymorphonuclear leu-
kocytes, can degrade many ECM components and are cru-
cially important in remodelling of connective tissues in devel-
opment, wound healing, angiogenesis, tumour invasion and
metastasis [11]. They include interstitial collagenases (MMP-
1, MMP-8, MMP-13), stromelysins (MMP-3 and MMP-10),
gelatinases (MMP-2 and MMP-9), matrilysin (MMP-7), mac-
rophage metalloelastase (MMP-12) and membrane type
MMPs (MT-MMPs). In this study, we have de¢ned sequences
at the proline-rich region of ¢brillin-1 and the glycine-rich
region of ¢brillin-2, and towards the carboxy-terminus of
the ¢brillin-1 molecules that are cleaved by MMPs. Their
predicted locations within assembled micro¢brils indicate
that MMP activity in physiologically and pathologically re-
modelling connective tissues could severely compromise the
structural and functional integrity of micro¢brils.
2. Materials and methods
2.1. Fibrillin cDNAs
Two ¢brillin cDNAs were constructed to generate mRNAs for
translation and digestion studies. They were (i) a ¢brillin-1 carboxy-
terminal cDNA clone (scFib-1) encoding exons 48^62 which was con-
structed from clone F3.4 [4], and (ii) a ¢brillin-1 amino-terminal
cDNA clone (nFib-1) encoding exons 1^15 which was constructed
from clone 5PF [4] (clones provided by Professor F. Ramirez, New
York). Three cDNAs were generated by RT-PCR for recombinant
expression and puri¢cation. Human dermal ¢broblast mRNA was
used to generate (a) cDNA encoding a three-domain ¢brillin-1 peptide
(pro¢b-1, exons 9^11) comprising the ¢rst TB module, the proline-rich
region and an EGF domain (pro¢b-1), and (b) cDNA encoding the
sixth TB module and its £anking cbEGF-like domains (3¢b-1, exons
49^51). Human keratinocyte mRNA was used to generate cDNA
encoding the glycine-rich region of ¢brillin-2 and £anking domains
(gly¢b-2, exons 9^11). The cDNAs encoding nFib-1, scFib-1, pro¢b-1
and gly¢b-2 were subcloned into the mammalian expression vector
pSecTag (Invitrogen) which has a secretion signal peptide from the
V-J2-C region of mouse Ig kappa-chain that allows e⁄cient trans-
location and secretion of recombinant proteins from mammalian cells.
Pro¢b-1 and gly¢b-2 constructs for expression in COS-1 cells had an
in-frame c-myc epitope and a six-histidine residue tag at their 3P end
that enabled puri¢cation using ProBond resin (Invitrogen). This is a
nickel-charged Sepharose resin to which recombinant proteins con-
taining a polyhistidine binding domain bind in 20 mM sodium phos-
phate bu¡er pH 7.8, but may subsequently be eluted by competition
with imidazole. The 3¢b-1 cDNA was subcloned into vector Signal
pIg (R and D Systems, UK). This vector has the CD33 signal se-
quence, and an IgG Fc tail that enables puri¢cation of recombinant
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peptides by protein A-Sepharose chromatography. An enterokinase
cleavage site was engineered preceding the Fc tail to allow elution
of puri¢ed 3¢b-1 peptide from the columns. Full sequences of all
cDNAs, vector modi¢cations, and correct vector insertions, were con-
¢rmed by dye-terminator automated sequencing.
2.2. Transcription and translation of ¢brillin cDNAs
nFib-1, scFib-1 and pro¢b-1 were subcloned into vector pSecTagA,
linearised, puri¢ed by phenol-chloroform extraction, then transcribed
using T7 RNA polymerase at 37‡C for 3 h. Column puri¢ed RNA
(Qiagen) was eluted in 50 Wl RNase-free water, with 1 mM dithio-
threitol and 40 units RNase inhibitor added, then heated to 60‡C for
10 min prior to use to disrupt secondary structure. For translations,
semi-permeabilised HT1080 cells were prepared as previously de-
scribed [12^15]. This system has been shown very e¡ectively to recap-
itulate correct folding and post-translational modi¢cations of newly
translocated proteins destined for the extracellular matrix. Fibrillin-1
RNA was translated in the presence of semi-permeabilised HT1080
cells using a rabbit reticulocyte lysate (Flexilysate, Promega, South-
ampton, UK) for 1.5 h at 30‡C. Each reaction contained 35 Wl lysate,
1 Wl RNase inhibitor, 1 Wl amino acids minus methionine or cysteine,
1 Wl potassium chloride, 2.5 Wl 35S methionine (15 WCi) or 3 Wl 35S
cysteine (10 WCi/Wl) and 2.5 Wl prepared RNA. Proteinase K and
endoglycosidase H digestions were carried out to con¢rm that newly
translated molecules had been translocated and N-glycosylated within
the endoplasmic reticulum, as previously documented [12^15]. In this
system, ¢brillin was the only labelled translated protein generated.
2.3. Recombinant expression in mammalian cells
COS-1 cells were transfected with gly¢b-2 or pro¢b-1 constructs in
pSecTag by electroporation, then incubated for 1 week at 37‡C in
Dulbecco’s modi¢ed Eagle’s medium (DMEM3) with 1% foetal calf
serum, 1% streptomycin, penicillin and glutamine, which had been
pre-cleared with ProBond resin (Invitrogen) by preincubation on a
rotator for 2 h at 4‡C prior to removal of resin by ¢ltration. Cellular
debris was removed by centrifugation at 4000Ug for 15 min and the
supernatant incubated at 4‡C for 18 h with 2 ml of ProBond resin.
The resin with bound recombinant proteins was collected in a scin-
tered glass funnel, washed with bu¡er (20 mM sodium phosphate pH
7.8), then with bu¡er containing 500 mM sodium chloride. Recombi-
nant proteins were eluted with bu¡er containing 200 mM or 500 mM
imidazole, and puri¢ed by size fractionation on a Superdex 200 PC
3.2/30 column using an AKTA Puri¢er system. Recombinant 3¢b-1
peptide was puri¢ed from transiently transfected COS-1 cell medium
by adsorption onto a protein A Sepharose column then elution after
enterokinase cleavage of the Fc tail. N-linked oligosaccharides were
removed from recombinant proteins by digestion with N-glycosidase
F in 100 mM KH2PO4 bu¡er, pH 7.2 at 37‡C for 24 h.
2.4. MMP digestions
ProMMP-2 was activated by pretreatment with 4-aminophenylmer-
curic acid (APMA) for 1 h at 25‡C. ProMMP-9 was activated by
pretreatment with APMA for 1.5 h at 37‡C. MMP-12, MMP-13
and MMP-14 (also known as MT-MMP1) did not require activation.
MMP-2, MMP-9, MMP-13 and MMP-14 were supplied by Professor
G. Murphy, Norwich, UK. MMP-12 was supplied by Professor S.
Shapiro, St. Louis, USA.
Aliquots (50 Wl) of puri¢ed recombinant ¢brillin peptides (15 Wg) or
35S-labelled recombinant nFib-1, scFib-1 pro¢b-1 and gly¢b-2 were
incubated with 5 Wl of 0.1 M calcium chloride and 5 Wl of either
MMP-2 (¢nal concentration 26 Wg/ml), MMP-9 (¢nal concentration
29 Wg/ml), MMP-12 (¢nal concentration 28 Wg/ml), MMP-13 (¢nal
concentration 8 Wg/ml) or MMP-14 (¢nal concentration 0.124 WM)
at 37‡C for 2^20 h.
2.5. Analysis of ¢brillin MMP degradation products
MMP-treated recombinant 35S-labelled ¢brillin molecules were re-
solved on 8% or 15% SDS-PAGE gels in reducing conditions and
visualised by autoradiography. Puri¢ed recombinant pro¢b-1, gly¢b-
2 and 3¢b-1 were electrophoresed on 15% gels, before and after MMP
incubations, in the presence of 50 mM dithiothreitol then stained with
Coomassie Brilliant Blue or blotted onto nitrocellulose membrane
using a semi-dry blotting apparatus. Carboxy-terminal pro¢b-1 and
gly¢b-2 cleavage fragments were identi¢ed by Western blotting using
a c-myc epitope primary antibody (Invitrogen) at 1:5000 dilution then
anti-mouse IgG horse radish peroxidase-conjugated secondary anti-
body (Sigma Chemical Company, Dorset, UK) at a 1:3000 dilution
and chemiluminescence (ECL) detection (Amersham, UK).
2.6. Protein sequencing
Recombinant pro¢b-1, gly¢b-2 and 3¢b-1 were electrophoresed in
the presence of 0.1 mM sodium thioglycollate on 15% SDS-PAGE
gels before and after MMP treatment, in the presence of 50 mM
dithiothreitol. The gels were blotted using a semi-dry procedure
onto PVDF membranes, then stained with Coomassie Brilliant Blue.
Cleavage fragments were sequenced by amino-terminal automated
sequencing. Duplicate cleavage products from di¡erent recombinant
peptide batches were sequenced.
3. Results
3.1. MMP digestion of recombinant 35S-labelled ¢brillin
molecules
The predicted Mrs, prior to N-glycosylation, of 35S-labelled
nFib-1 and scFib-1 generated using semi-permeabilised
HT1080 cells were 68 kDa and 70 kDa, respectively, but their
apparent Mrs by SDS-PAGE were 75 kDa and 90 kDa (Fig.
1). nFib-1 and pro¢b-1 were each cleaved by MMP-2, MMP-
9, MMP-12, MMP-13 and MMP-14, producing major frag-
ments of V45 kDa and 10^12 kDa, respectively (Fig. 1).
scFib-1 was also cleaved by the ¢ve MMPs and a major prod-
uct (62 kDa) plus some minor products were generated (Fig.
1).
3.2. MMP digestion of recombinant ¢brillin three-domain
peptides
Recombinant three-domain peptides predicted to span the
cleavage sites identi¢ed in nFib-1 and scFib-1 were expressed
in COS-1 cells and puri¢ed in order to de¢ne the cleavage
sequences (see Table 1). Pro¢b-1, gly¢b-2 and 3¢b-1 peptides
had apparent Mrs ofV30 kDa and all were N-glycosylated as
judged by increased mobility following N-glycosidase F treat-
ment (not shown). When pro¢b-1 was treated with MMP-9
and MMP-13, it was cleaved into fragments of V10 and
14 kDa. A similar fragmentation pattern was seen for the
labelled ¢brillin-1 molecules generated in the semi-permeabi-
lised HT1080 cell system; additional minor faster migrating
bands were also apparent in those preparations. Duplicate
amino acid sequencing identi¢ed the smaller product as the
amino-terminal peptide fragment, and the N-terminal se-
quence of the carboxy-terminal fragment generated by both
enzymes was VTDYCQLVRY (residues 449^458) [4]. Thus,
the cleavage site is located within the NsVT N-glycosylation
Table 1
Amino-terminal sequences of peptides generated by MMP cleavage
Peptide MMP N-terminal sequences
Pro¢b-1 MMP-9 V449TDYCQLVRY
MMP-13 V449TDYCQLVRY
Gly¢b-2 MMP-2 T488IL-QTIDI
MMP-2 L487TILGQTID
MMP-9 T488IL-QTIDI
MMP-12 T488IL-Q(T)IDI
MMP-13 L487TIDGQTID
3¢b-1 MMP-12 L2046S-SGRRCQD
All amino-terminal sequencing reactions of MMP-generated car-
boxy-terminal fragments were con¢rmed by sequencing of products
from two separate experiments. In one case (MMP-2, gly¢b-2), the
initial amino acid di¡ered by a single residue. The residue numbers
of the ¢rst amino acid are denoted in superscript for each ¢brillin-1
and ¢brillin-2 peptide analysed [4,5].
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sequence just after the exon 10/11 junction (see Fig. 2). Gly¢b-
2 was treated with all ¢ve enzymes; in each case fragments of
10^14 kDa were generated as previously demonstrated using
the semi-permeabilised HT1080 cell system. Treatment with
MMP-9 and MMP-12 produced carboxy-terminal fragments
starting with the sequence TILQTIDI (residues 488^495) [5].
Sequencing of the carboxy-terminal MMP-2 fragment gener-
ated in duplicate preparations revealed products di¡ering by a
single amino acid (TILQTIDI and LTILQTIDI respectively).
Treatment with MMP-13 and MMP-14 generated fragments
starting with the sequence LTILQTIDI (residues 487^495).
The gly¢b-2 cleavage site is thus also located at the exon
10/11 junction (see Fig. 2). Western blotting using the anti-
c-myc antibody con¢rmed that the V14 kDa bands from
pro¢b-1 and gly¢b-2 were carboxy-terminal cleavage products
(not shown). Treatment of 3¢b-1 peptide with MMP-12 pro-
duced fragments ofV12^14 kDa. The N-terminal sequence of
the carboxy-terminal fragment of 3¢b-1 was LSSSGRRCQD
(residues 2046^2055) [4] indicating that this cleavage site is
close to the carboxy-terminus of exon 49 [4] (see Fig. 2).
4. Discussion
This study has demonstrated that ¢brillin molecules are
readily cleaved by several MMPs at the exon 10/11 junction
and the carboxy-terminal end of exon 49, respectively. Using a
recombinant approach, we identi¢ed major MMP degradation
products of nFib-1 and scFib-1 and went on to de¢ne three
readily cleavable sequences at the carboxy-terminal ends of
the proline-rich region of ¢brillin-1 and the corresponding
glycine-rich region of ¢brillin-2, and towards the carboxy-ter-
minus of ¢brillin-1.
The presence of a leucine (L) residue in the P1P position of
3¢b-1 and gly¢b-2 fragments after MMP-13 and MT1-MMP
treatments is consistent with known MMP cleavage site pref-
erences [11]. The P1P residue of gly¢b-2 fragments generated
by MMP-2, MMP-9 and MMP-12 was the threonine (T) res-
idue after this leucine (residue 487) [5], con¢rming this region
to be highly susceptible to proteolytic attack. The amino acid
sequences of the fragments of pro¢b-1 generated with MMP-9
and MMP-13 indicated that cleavage had occurred within the
NVT consensus sequence. Since the presence of carbohydrate
could inhibit potential MMP directed cleavage, we con¢rmed
that these peptides were indeed N-glycosylated at this site,
although we cannot exclude that a small amount of unglyco-
sylated peptide was also present.
MMP cleavage of ¢brillin molecules is likely to be crucial in
the physiological and pathological turnover of micro¢brils in
connective tissues. Since micro¢brils probably contain almost
full-length furin-trimmed ¢brillin molecules [6], it seems un-
likely that MMPs normally ‘process’ newly synthesised ¢bril-
lin at the sites identi¢ed here prior to assembly. More likely,
¢brillin molecules may be proteolytically susceptible to MMP
degradation prior to, or following micro¢bril formation.
Fig. 2. MMP cleavage sites in ¢brillin. A: Domain structure of ¢-
brillin-1 showing the locations of the MMP cleavage sites (u) iden-
ti¢ed in this study. The sequences £anking the cleavage sites are
highlighted. The ¢brillin-2 gly¢b-2 cleavage site is also shown for
comparison. Exon junctions are highlighted by asterisks [4]. B: The
likely locations of the proline-rich region and exon 49 within the in-
terbeads of assembled micro¢brils [6].
Fig. 1. MMP digestions of nFib-1, pro¢b-1 and scFib-1. 35S-labelled nFib-1 and scFib-1 were analysed on 8% SDS-PAGE gels in reducing con-
ditions, and pro¢b-1 was analysed on an 15% SDS-PAGE gel in reducing conditions. MMP digestions of recombinant molecules were carried
out as described in Section 2. Major cleavage products are highlighted by arrows. Numbers above tracks indicate which MMP enzyme the pro-
tein has been treated with. C indicates untreated control samples.
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MMP cleavage of ¢brillin within assembled micro¢brils would
undoubtedly compromise micro¢bril structure and function
(see Fig. 2), and contribute to the destruction of extracellular
matrix in in£ammatory and infective states characterised by
release and activation of MMPs by neutrophils, leukocytes
and macrophages. Since micro¢brils are stabilised by intermo-
lecular covalent cross-links [12,13], it is unclear whether
cleaved terminal ¢brillin fragments would actually be released
from damaged micro¢brils. If so, their detection in blood and
excretory products may turn out to be a useful diagnostic
marker for micro¢bril damage in Marfan syndrome and age-
ing diseases.
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